Analysts Expect CASI Pharmaceuticals Inc (CASI) Will Post Earnings of -$0.07 Per Share

Brokerages expect CASI Pharmaceuticals Inc (NASDAQ:CASI) to announce earnings of ($0.07) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for CASI Pharmaceuticals’ earnings. CASI Pharmaceuticals reported earnings of ($0.04) per share in the same quarter last year, which indicates a negative year over year growth rate of 75%. The business is scheduled to issue its next earnings results on Monday, August 13th.

According to Zacks, analysts expect that CASI Pharmaceuticals will report full-year earnings of ($0.22) per share for the current financial year, with EPS estimates ranging from ($0.28) to ($0.16). For the next year, analysts forecast that the company will post earnings of ($0.16) per share, with EPS estimates ranging from ($0.19) to ($0.13). Zacks’ EPS averages are an average based on a survey of analysts that cover CASI Pharmaceuticals.

CASI Pharmaceuticals (NASDAQ:CASI) last posted its quarterly earnings results on Tuesday, May 15th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02.

Several research firms have recently weighed in on CASI. BidaskClub downgraded CASI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 13th. ValuEngine upgraded CASI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd.

Several hedge funds have recently bought and sold shares of CASI. State Board of Administration of Florida Retirement System bought a new position in shares of CASI Pharmaceuticals during the 2nd quarter worth $101,000. Strs Ohio bought a new position in CASI Pharmaceuticals in the 2nd quarter worth about $108,000. Millennium Management LLC bought a new position in CASI Pharmaceuticals in the 4th quarter worth about $137,000. First Manhattan Co. bought a new position in CASI Pharmaceuticals in the 2nd quarter worth about $246,000. Finally, Rhumbline Advisers bought a new position in CASI Pharmaceuticals in the 2nd quarter worth about $374,000. Institutional investors own 5.75% of the company’s stock.

Shares of CASI Pharmaceuticals traded up $0.59, hitting $7.89, on Tuesday, Marketbeat reports. 766,646 shares of the stock were exchanged, compared to its average volume of 245,942. The company has a current ratio of 25.53, a quick ratio of 25.53 and a debt-to-equity ratio of 0.02. CASI Pharmaceuticals has a one year low of $0.93 and a one year high of $8.42.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma and triple-negative breast cancer.

See Also: Outstanding Shares and The Effect on Share Price

Get a free copy of the Zacks research report on CASI Pharmaceuticals (CASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply